The global lung cancer surgery market is estimated to account for USD 1.4 billion in 2024. It is anticipated to grow at a CAGR of 5.7% during the assessment period and reach a value of USD 2.5 billion by 2034.
| Attributes | Description |
|---|---|
| Estimated Global Lung Cancer Surgery Market Size (2024E) | USD 1.4 billion |
| Projected Global Lung Cancer Surgery Market Value (2034F) | USD 2.5 billion |
| Value-based CAGR (2024 to 2034) | 5.7% |
There are around 1 billion smokers in the world and this number is very likely to surge in the coming decade. Smoking is one of the leading reasons for lung cancer. It increases the risk of lung cancer by over 15 times and is responsible for over 80% of deaths due to lung cancer.
In scenarios like this, patients diagnosed with lung cancer are opting for surgery as it can potentially remove the tumor entirely. Surgery also offers a chance for a cure, especially in early-stage lung cancer.
Various other factors are also motivating people to go for lung cancer surgeries. Government policies in countries like India, China, Thailand, etc., curated specially to include the economically underprivileged individuals. This has helped them access timely lung cancer surgeries and treatments.
For instance, the Health Minister's Cancer Patient Fund (HMCPF) in India provides significant financial assistance for cancer treatment. This has positively affected the market as India is becoming a hub for affordable cancer care, attracting both domestic and international patients seeking treatment.
Public health campaigns have helped people detect the cancer in its early stages. With improved screening methods, such as low-dose CT scans, the efficiency of these tests have improved drastically. Health consciousness trends among the general populace, post-pandemic, have also played a significant role in encouraging people to go for these tests. This has made surgical treatment a more viable option for many patients.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The table exhibits the estimated CAGR for the global lung cancer surgery market over semi-annual periods between 2023 and 2024. The analysis provides organizations with a better understanding of the growth over the year by divulging crucial shifts in performance and growth patterns. The first half (H1) of 2023 spans from January to June. The second half (H2) includes July to December.
Figures presented in the below table exhibit the growth rate for each half from 2023 to 2024. The market is anticipated to grow at a CAGR of 6.4% in the first half (H1) of 2023. The second half of the same year is estimated to witness a plunge in the CAGR at 6.1%.
| Particular | Value CAGR |
|---|---|
| H1 | 6.4% (2023 to 2033) |
| H2 | 6.1% (2023 to 2033) |
| H1 | 5.7% (2024 to 2034) |
| H2 | 5.2% (2024 to 2034) |
Moving in the following period, from H1 2024 to H2 2034, the CAGR is projected to dip to 5.7% in the first half (H1) and then fall to 5.2% in the second half (H2).
Success Stories from Celebrities and Public Figures to Play a Significant Role
Celebrities, these days, are not shying away from sharing their lung cancer journeys. This has significantly increased the awareness regarding these surgeries which were hitherto overlooked or stigmatized. Stories like these also help normalize the conversation around lung cancer and its treatment options. This has made lung cancer surgeries less stigmatized and more acceptable for individuals to seek help.
For instance, in December 2023, actress Kate Micucci, known for her role on ‘Big Bang Theory’, revealed she underwent lung cancer surgery. Despite never having smoked, she emphasized early detection was crucial. By sharing her experience, Micucci tried to inspire individuals to prioritize their health and take proactive steps in their cancer journey.
Novel Technologies in Lung Cancer Surgeries to Enhance Treatment Outcomes
Scientific breakthroughs in the Medicare sector have changed the whole dynamics of the market in the past few years. Healthcare entities, both private and public, are investing billions of dollars into developing new technologies. Robotic arms like the da Vinci Surgical System, which allows for minimally invasive procedures with greater precision and control have made a successful entry into the medical world.
Video-Assisted Thoracoscopic Surgery (VATS) and other minimally invasive techniques that use a small camera and specialized instruments to perform lung surgery have also gained popularity.
Factors Impeding the Market Growth
Principal Consultant
The global lung cancer surgery industry was valued at USD 1.03 billion in 2019. It grew at a CAGR of 7.6% during the historical period to reach a size of USD 1.3 billion in 2023.
In the last few years, the market has shown much instability. When the first wave of pandemic hit the world, many elective surgeries were postponed to prioritize COVID-19 patients. This, obviously, led to a decline in lung cancer diagnoses and treatments. Some patients also, reportedly, feared visiting hospitals due to infection risks.
Early detection rates during this period also dropped dramatically as healthcare facilities shifted focus to managing the pandemic. This affected the market negatively. The market soon showed some signs of recovery as hospitals started resuming elective surgeries with safety protocols.
Telemedicine activities, which enabled remote consultations, also gained popularity during this period. Backlogs of surgeries meant healthcare facilities had more patients than ever before. This surge in treatments generated an excellent demand for equipment required in these surgeries. This helped the market stand back on its feet.
By 2023, as vaccination efforts improved, patients gained confidence in seeking care. Hospitals and NGOs started early detection programs. The market, thus, saw an increase in surgical procedures, due to these efforts. Patients who delayed treatments also began to seek care.
Tier one companies in the market such as Asap Endoscopic Products, Ethicon Inc. (J & J), Medtronic Plc., Germed USA Inc., and Teleflex Incorporated, have been in the industry since ages. They have been successful in establishing strong brand recognition and trust. These companies, thanks to their enormous financial might, invest heavily in research and development. This has led to innovative solutions and improved patient outcomes.
Meanwhile, companies in the second tier are the ones that generally operate on a regional level. Their consumer base is often restricted within the confines of the country in which they are situated. Government bodies often tie-up with these institutions so as to enhance local healthcare services. They also provide competitive pricing to attract local customers.
Companies in the third-tier are local hospital chains and equipment manufacturers. These players lack the financial resources top-tier companies have. It is because of this reason, technological advancements reach very late in their facilities. Some of them even struggle to maintain basic equipment and services. Limited budgets hinder their ability to invest in new technologies.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The below section provides companies with an overview of the industry. It comprises a detailed analysis of the emerging trends and opportunities on a country-by-country basis. This country-specific examination of the industry dynamics is estimated to help businesses understand the industry's complex nature.
India is estimated to dominate the country-wise growth in the industry during the forecast period with a predicted CAGR of 6.9%. China, Japan, and Germany are projected to follow behind India to become the key countries in the industry with anticipated CAGRs of 6.5%, 3.4%, and 1.7% respectively.
| Countries | CAGR 2024 to 2034 |
|---|---|
| India | 6.9% |
| China | 6.5% |
| Japan | 3.4% |
| Germany | 1.7% |
| The United States | 1.7% |
India is poised to emerge as the dominating country in the lung cancer surgery market over the assessment period with a CAGR of 6.9%.
Lung cancer in India is a very serious problem. Healthcare facilities, both private and public, have made significant efforts in mitigating the impact. It is the fourth most common cancer in India, accounting for 5.9% of all cancer cases. This scenario creates a conducive environment for players involved in the market.
The prevalence of ‘bidi’, an indigenous cigarette, has also been one of the major contributors to lung cancer rates. This has also contributed to a higher incidence of lung cancer, necessitating more surgical interventions.
The lung cancer surgery market in China is estimated to grow at a CAGR of 5.2% from 2024 to 2034.
China is home to one of the largest geriatric populations in the world. This demographic is very susceptible to lung cancer. The elderly, throughout their life, are more likely to have been exposed to risk factors such as smoking, environmental pollutants, and occupational hazards. This contributes to higher lung cancer rates.
Pollution is China is also a major problem and a reason for the rising incidence of lung cancer. This has prompted the government to implement stricter regulations in the country, which has positioned China among the leading countries in this market.
The United States lung cancer surgery market is anticipated to grow at a CAGR of 1.7% during the forecast period.
The United States is blessed with one of the best healthcare systems in the world. The country hosts several well-established hospital chains where people can avail affordable surgeries. Insurance schemes and healthcare coverage play a crucial role in facilitating access to lung cancer treatments. This allows patients to receive timely and necessary surgical interventions without facing prohibitive costs.
Moreover, in 2024, around 125,070 people succumbed to lung cancer in the United States. However, the mortality rate and the number of new lung cancer diagnoses have been declining in the country since 2006. This is due to the well-established healthcare infrastructure and availability of advanced treatment solutions.
In addition, with reduced time taken for regulatory approvals and costs for the device, the device manufacturers are eyeing the United States market for premarket submissions. This is expected to create conducive environment for the key players, boosting the market.
The section offers companies with insightful data and analysis of the two leading segments. Segmentation of these categories is predicted to help organizations understand the dynamics of the industry and invest in beneficial zones.
On the basis of products, the market is segmented into thoracoscopes, mediastinoscopes, bronchoscopes, robotic-assisted thoracic surgery systems, surgical staplers, and surgical energy instruments. Among these, surgical energy instruments hold a majority share of 42.5%, as of 2024.
| Segment | Surgical Energy Equipment (Product) |
|---|---|
| Value Share (2024) | 42.5% |
Patient outcomes have significantly improved over the years due to scientific breakthroughs in the Medicare industry. Advanced surgical energy equipment allows surgeons to perform procedures with greater accuracy. They also minimize the damage to surrounding tissues.
The demand for surgical energy equipment is also touching the skies these devices come with features that enhance safety. They are also comparatively less invasive which often leads to shorter recovery times for patients.
On the basis of applications, the market is segmented into lobectomy, segmentectomy, wedge resection, and pneumonectomy. Among these, lobectomy holds a majority share of 67.3%, as of 2024.
| Segment | Lobectomy (Application) |
|---|---|
| Value Share (2024) | 67.3% |
Lobectomy, a surgical procedure involving the removal of a lobe of the lung, is often the preferred surgical option for patients with localized lung cancer. This is because, it allows for the complete removal of the tumor along with a margin of healthy tissue. This reduces the risk of cancer recurrence, particularly non-small cell lung cancer (NSCLC).
It is also considered a standard treatment and surgeons frequently recommend this procedure due to its effectiveness in removing cancerous tissues while preserving lung function. With more awareness and early detection of lung cancer through screening programs, the demand for lobectomy is very likely to skyrocket.
The competition in the market for lung cancer surgery is very fierce as the healthcare world is flooded with a variety of surgical procedures, such as lobectomy, wedge resection, and pneumonectomy. This competition is also influenced by the reimbursement landscape of that particular region. More well-established the healthcare systems, better the resources and technologies they can provide.
Some of the prominent companies in the market are Asap Endoscopic Products, Ethicon Inc. (J & J), Medtronic Plc., Germed USA Inc., and Teleflex Incorporated.
Industry Updates
By product, the market includes thoracoscopes, mediastinoscopes, bronchoscopes, robotic-assisted thoracic surgery systems, surgical staplers, surgical energy instruments, advanced energy instruments, advanced bipolar instruments, ultrasonic instruments, basic energy instruments, bipolar instruments, and monopolar instruments.
By application, the primary procedures are lobectomy, segmentectomy, wedge resection, and pneumonectomy.
By end-user, the market is divided into hospitals and ambulatory surgical centres.
The industry is spread across North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.
The market is estimated to reach USD 1.4 billion in 2024.
The market is predicted to reach a size of USD 2.5 billion by 2034.
Asap Endoscopic Products, Ethicon Inc. (J & J), Medtronic Plc., Germed USA Inc., and Teleflex Incorporated.
It is predicted to witness a CAGR of 5.7% during the forecast period.
India is projected to dominate with a CAGR of 6.9% during the assessment period.
Explore Healthcare Insights
View Reports
Lung Cancer Surgery Market
